ID   TRPM7_HUMAN             Reviewed;        1865 AA.
AC   Q96QT4; Q6ZMF5; Q86VJ4; Q8NBW2; Q9BXB2; Q9NXQ2;
DT   07-DEC-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2001, sequence version 1.
DT   12-OCT-2022, entry version 172.
DE   RecName: Full=Transient receptor potential cation channel subfamily M member 7;
DE            EC=2.7.11.1;
DE   AltName: Full=Channel-kinase 1;
DE   AltName: Full=Long transient receptor potential channel 7;
DE            Short=LTrpC-7;
DE            Short=LTrpC7;
GN   Name=TRPM7; Synonyms=CHAK1, LTRPC7;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND CHARACTERIZATION.
RX   PubMed=11385574; DOI=10.1038/35079092;
RA   Nadler M.J.S., Hermosura M.C., Inabe K., Perraud A.-L., Zhu Q.,
RA   Stokes A.J., Kurosaki T., Kinet J.-P., Penner R., Scharenberg A.M.,
RA   Fleig A.;
RT   "LTRPC7 is a Mg.ATP-regulated divalent cation channel required for cell
RT   viability.";
RL   Nature 411:590-595(2001).
RN   [2]
RP   ERRATUM OF PUBMED:11385574.
RA   Nadler M.J.S., Hermosura M.C., Inabe K., Perraud A.-L., Zhu Q.,
RA   Stokes A.J., Kurosaki T., Kinet J.-P., Penner R., Scharenberg A.M.,
RA   Fleig A.;
RL   Nature 412:660-660(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND CHARACTERIZATION.
RX   PubMed=14594813; DOI=10.1074/jbc.m308820200;
RA   Ryazanova L.V., Dorovkov M.V., Ansari A., Ryazanov A.G.;
RT   "Characterization of the protein kinase activity of TRPM7/ChaK1, a protein
RT   kinase fused to the transient receptor potential ion channel.";
RL   J. Biol. Chem. 279:3708-3716(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-575 AND 1096-1865, AND VARIANT
RP   ILE-1482.
RC   TISSUE=Colon, and Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 464-998.
RC   TISSUE=Liver;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   FUNCTION, AND MUTAGENESIS OF LYS-1648 AND GLY-1799.
RX   PubMed=12887921; DOI=10.1016/s0092-8674(03)00556-7;
RA   Schmitz C., Perraud A.-L., Johnson C.O., Inabe K., Smith M.K., Penner R.,
RA   Kurosaki T., Fleig A., Scharenberg A.M.;
RT   "Regulation of vertebrate cellular Mg2+ homeostasis by TRPM7.";
RL   Cell 114:191-200(2003).
RN   [7]
RP   FUNCTION.
RX   PubMed=15485879; DOI=10.1074/jbc.c400441200;
RA   Dorovkov M.V., Ryazanov A.G.;
RT   "Phosphorylation of annexin I by TRPM7 channel-kinase.";
RL   J. Biol. Chem. 279:50643-50646(2004).
RN   [8]
RP   INTERACTION WITH TRPM6.
RX   PubMed=14976260; DOI=10.1073/pnas.0305252101;
RA   Chubanov V., Waldegger S., Mederos y Schnitzler M., Vitzthum H.,
RA   Sassen M.C., Seyberth H.W., Konrad M., Gudermann T.;
RT   "Disruption of TRPM6/TRPM7 complex formation by a mutation in the TRPM6
RT   gene causes hypomagnesemia with secondary hypocalcemia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:2894-2899(2004).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1477, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [11]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-101; SER-1387; SER-1390;
RP   SER-1395; SER-1404; SER-1477; SER-1527 AND SER-1569, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [13]
RP   FUNCTION.
RX   PubMed=24316671; DOI=10.1038/ncb2883;
RA   Cai Z., Jitkaew S., Zhao J., Chiang H.C., Choksi S., Liu J., Ward Y.,
RA   Wu L.G., Liu Z.G.;
RT   "Plasma membrane translocation of trimerized MLKL protein is required for
RT   TNF-induced necroptosis.";
RL   Nat. Cell Biol. 16:55-65(2014).
RN   [14]
RP   VARIANT ILE-1482, AND CHARACTERIZATION OF VARIANT ILE-1482.
RX   PubMed=16051700; DOI=10.1073/pnas.0505149102;
RA   Hermosura M.C., Nayakanti H., Dorovkov M.V., Calderon F.R., Ryazanov A.G.,
RA   Haymer D.S., Garruto R.M.;
RT   "A TRPM7 variant shows altered sensitivity to magnesium that may contribute
RT   to the pathogenesis of two Guamanian neurodegenerative disorders.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:11510-11515(2005).
RN   [15]
RP   VARIANTS [LARGE SCALE ANALYSIS] VAL-68; CYS-406; THR-459; ASN-574; SER-720;
RP   VAL-830; TYR-949; ARG-1064; THR-1211; VAL-1254; GLU-1306; LYS-1444 AND
RP   ILE-1482.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [16]
RP   VARIANT ASP-1046, CHARACTERIZATION OF VARIANT ASP-1046, INVOLVEMENT IN
RP   HYPOMAGNESEMIA WITH SECONDARY HYPOCALCEMIA, AND FUNCTION.
RX   PubMed=35561741; DOI=10.1093/ndt/gfac182;
RA   Vargas-Poussou R., Claverie-Martin F., Prot-Bertoye C., Carotti V.,
RA   van der Wijst J., Perdomo-Ramirez A., Fraga-Rodriguez G.M., Hureaux M.,
RA   Bos C., Latta F., Houillier P., Hoenderop J., de Baaij J.;
RT   "Possible role for rare TRPM7 variants in patients with hypomagnesemia with
RT   secondary hypocalcemia.";
RL   Nephrol. Dial. Transplant. 0:0-0(2022).
CC   -!- FUNCTION: Essential ion channel and serine/threonine-protein kinase.
CC       Divalent cation channel permeable to calcium and magnesium
CC       (PubMed:35561741). Has a central role in magnesium ion homeostasis and
CC       in the regulation of anoxic neuronal cell death. Involved in TNF-
CC       induced necroptosis downstream of MLKL by mediating calcium influx. The
CC       kinase activity is essential for the channel function. May be involved
CC       in a fundamental process that adjusts plasma membrane divalent cation
CC       fluxes according to the metabolic state of the cell. Phosphorylates
CC       annexin A1 (ANXA1). {ECO:0000269|PubMed:12887921,
CC       ECO:0000269|PubMed:15485879, ECO:0000269|PubMed:24316671,
CC       ECO:0000269|PubMed:35561741}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1;
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000250};
CC   -!- SUBUNIT: Homodimer. Interacts with PLCB1 (By similarity). Forms
CC       heterodimers with TRPM6. {ECO:0000250, ECO:0000269|PubMed:14976260}.
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000305}; Multi-pass membrane
CC       protein {ECO:0000305}.
CC   -!- PTM: Autophosphorylated. {ECO:0000250}.
CC   -!- DISEASE: Amyotrophic lateral sclerosis-parkinsonism/dementia complex 1
CC       (ALS-PDC1) [MIM:105500]: A neurodegenerative disorder characterized by
CC       chronic, progressive and uniformly fatal amyotrophic lateral sclerosis
CC       and parkinsonism-dementia. Both diseases are known to occur in the same
CC       kindred, the same sibship and even the same individual. Note=Disease
CC       susceptibility is associated with variants affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Note=TRPM7 variants have been identified as a potential cause
CC       of disease in patients suffering from seizures and muscle cramps due to
CC       magnesium deficiency and episodes of hypocalcemia.
CC       {ECO:0000269|PubMed:35561741}.
CC   -!- SIMILARITY: In the C-terminal section; belongs to the protein kinase
CC       superfamily. Alpha-type protein kinase family. ALPK subfamily.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: In the N-terminal section; belongs to the transient
CC       receptor (TC 1.A.4) family. LTrpC subfamily. TRPM7 sub-subfamily.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAC11462.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=BAD18773.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY032950; AAK44211.1; -; mRNA.
DR   EMBL; AF346629; AAK19738.2; -; mRNA.
DR   EMBL; AK000124; BAA90958.1; -; mRNA.
DR   EMBL; AK172800; BAD18773.1; ALT_INIT; mRNA.
DR   EMBL; AK075193; BAC11462.1; ALT_INIT; mRNA.
DR   EMBL; BC051024; AAH51024.1; -; mRNA.
DR   CCDS; CCDS42035.1; -.
DR   RefSeq; NP_001288141.1; NM_001301212.1.
DR   RefSeq; NP_060142.3; NM_017672.5.
DR   AlphaFoldDB; Q96QT4; -.
DR   SMR; Q96QT4; -.
DR   BioGRID; 120177; 133.
DR   CORUM; Q96QT4; -.
DR   IntAct; Q96QT4; 16.
DR   MINT; Q96QT4; -.
DR   STRING; 9606.ENSP00000320239; -.
DR   BindingDB; Q96QT4; -.
DR   ChEMBL; CHEMBL1250412; -.
DR   DrugBank; DB04447; 1,4-Dithiothreitol.
DR   DrugBank; DB14513; Magnesium.
DR   DrugBank; DB09481; Magnesium carbonate.
DR   DrugBank; DB04395; Phosphoaminophosphonic Acid-Adenylate Ester.
DR   GuidetoPHARMACOLOGY; 499; -.
DR   TCDB; 1.A.4.5.1; the transient receptor potential ca2+ channel (trp-cc) family.
DR   CarbonylDB; Q96QT4; -.
DR   iPTMnet; Q96QT4; -.
DR   PhosphoSitePlus; Q96QT4; -.
DR   BioMuta; TRPM7; -.
DR   DMDM; 56404941; -.
DR   EPD; Q96QT4; -.
DR   jPOST; Q96QT4; -.
DR   MassIVE; Q96QT4; -.
DR   MaxQB; Q96QT4; -.
DR   PaxDb; Q96QT4; -.
DR   PeptideAtlas; Q96QT4; -.
DR   PRIDE; Q96QT4; -.
DR   ProteomicsDB; 77898; -.
DR   Antibodypedia; 24755; 469 antibodies from 39 providers.
DR   DNASU; 54822; -.
DR   Ensembl; ENST00000646667.1; ENSP00000495860.1; ENSG00000092439.16.
DR   GeneID; 54822; -.
DR   KEGG; hsa:54822; -.
DR   MANE-Select; ENST00000646667.1; ENSP00000495860.1; NM_017672.6; NP_060142.3.
DR   UCSC; uc001zyt.5; human.
DR   CTD; 54822; -.
DR   DisGeNET; 54822; -.
DR   GeneCards; TRPM7; -.
DR   HGNC; HGNC:17994; TRPM7.
DR   HPA; ENSG00000092439; Tissue enhanced (parathyroid).
DR   MalaCards; TRPM7; -.
DR   MIM; 105500; phenotype.
DR   MIM; 605692; gene.
DR   neXtProt; NX_Q96QT4; -.
DR   OpenTargets; ENSG00000092439; -.
DR   Orphanet; 140957; Autosomal dominant macrothrombocytopenia.
DR   Orphanet; 90020; Parkinson-dementia complex of Guam.
DR   PharmGKB; PA38273; -.
DR   VEuPathDB; HostDB:ENSG00000092439; -.
DR   eggNOG; KOG3614; Eukaryota.
DR   GeneTree; ENSGT00940000157091; -.
DR   InParanoid; Q96QT4; -.
DR   OMA; ENNFQTA; -.
DR   OrthoDB; 738147at2759; -.
DR   PhylomeDB; Q96QT4; -.
DR   TreeFam; TF314204; -.
DR   PathwayCommons; Q96QT4; -.
DR   Reactome; R-HSA-3295583; TRP channels.
DR   SignaLink; Q96QT4; -.
DR   SIGNOR; Q96QT4; -.
DR   BioGRID-ORCS; 54822; 391 hits in 1114 CRISPR screens.
DR   ChiTaRS; TRPM7; human.
DR   GeneWiki; TRPM7; -.
DR   GenomeRNAi; 54822; -.
DR   Pharos; Q96QT4; Tchem.
DR   PRO; PR:Q96QT4; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   RNAct; Q96QT4; protein.
DR   Bgee; ENSG00000092439; Expressed in left ventricle myocardium and 177 other tissues.
DR   ExpressionAtlas; Q96QT4; baseline and differential.
DR   Genevisible; Q96QT4; HS.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0001726; C:ruffle; IEA:Ensembl.
DR   GO; GO:0003779; F:actin binding; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005262; F:calcium channel activity; IBA:GO_Central.
DR   GO; GO:0005261; F:cation channel activity; IBA:GO_Central.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0017022; F:myosin binding; IEA:Ensembl.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0031032; P:actomyosin structure organization; IEA:Ensembl.
DR   GO; GO:0070588; P:calcium ion transmembrane transport; TAS:Reactome.
DR   GO; GO:0006816; P:calcium ion transport; IBA:GO_Central.
DR   GO; GO:0016340; P:calcium-dependent cell-matrix adhesion; IEA:Ensembl.
DR   GO; GO:0098655; P:cation transmembrane transport; IBA:GO_Central.
DR   GO; GO:0010961; P:cellular magnesium ion homeostasis; IEA:InterPro.
DR   GO; GO:0072507; P:divalent inorganic cation homeostasis; IBA:GO_Central.
DR   GO; GO:0070266; P:necroptotic process; IMP:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IEA:Ensembl.
DR   GO; GO:0051262; P:protein tetramerization; IEA:InterPro.
DR   Gene3D; 1.20.5.1010; -; 1.
DR   InterPro; IPR005821; Ion_trans_dom.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR004166; MHCK_EF2_kinase.
DR   InterPro; IPR029601; TRPM7.
DR   InterPro; IPR041491; TRPM_SLOG.
DR   InterPro; IPR032415; TRPM_tetra.
DR   InterPro; IPR037162; TRPM_tetra_sf.
DR   PANTHER; PTHR13800:SF8; PTHR13800:SF8; 1.
DR   Pfam; PF02816; Alpha_kinase; 1.
DR   Pfam; PF00520; Ion_trans; 1.
DR   Pfam; PF18139; LSDAT_euk; 1.
DR   Pfam; PF16519; TRPM_tetra; 1.
DR   SMART; SM00811; Alpha_kinase; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51158; ALPHA_KINASE; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Amyotrophic lateral sclerosis; ATP-binding; Calcium;
KW   Calcium channel; Calcium transport; Coiled coil; Disease variant;
KW   Ion channel; Ion transport; Kinase; Membrane; Metal-binding; Necrosis;
KW   Neurodegeneration; Nucleotide-binding; Parkinsonism; Phosphoprotein;
KW   Reference proteome; Serine/threonine-protein kinase; Transferase;
KW   Transmembrane; Transmembrane helix; Transport; Zinc.
FT   CHAIN           1..1865
FT                   /note="Transient receptor potential cation channel
FT                   subfamily M member 7"
FT                   /id="PRO_0000215331"
FT   TOPO_DOM        1..755
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        756..776
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        777..855
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        856..876
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        877..918
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        919..939
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        940..962
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        963..983
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        984..995
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        996..1016
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        1017..1035
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   INTRAMEM        1036..1056
FT                   /note="Pore-forming"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        1057..1074
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        1075..1095
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        1096..1865
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          1594..1824
FT                   /note="Alpha-type protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00501"
FT   REGION          544..575
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1386..1407
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1492..1511
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1524..1543
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1836..1865
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          1198..1250
FT                   /evidence="ECO:0000250"
FT   COMPBIAS        544..562
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1843..1865
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        1767
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000250"
FT   BINDING         1624
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250"
FT   BINDING         1648
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250"
FT   BINDING         1720
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250"
FT   BINDING         1753
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250"
FT   BINDING         1769
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250"
FT   BINDING         1777
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250"
FT   BINDING         1794..1800
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250"
FT   BINDING         1810
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250"
FT   BINDING         1812
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250"
FT   BINDING         1816
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         101
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1224
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q923J1"
FT   MOD_RES         1255
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q923J1"
FT   MOD_RES         1301
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q923J1"
FT   MOD_RES         1386
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q923J1"
FT   MOD_RES         1387
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1390
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1395
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1404
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1405
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q923J1"
FT   MOD_RES         1446
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q923J1"
FT   MOD_RES         1467
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q923J1"
FT   MOD_RES         1477
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         1500
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q923J1"
FT   MOD_RES         1504
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q923J1"
FT   MOD_RES         1527
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1569
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1851
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q923J1"
FT   VARIANT         68
FT                   /note="G -> V (in dbSNP:rs56064201)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042395"
FT   VARIANT         406
FT                   /note="S -> C (in an ovarian serous carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042396"
FT   VARIANT         459
FT                   /note="I -> T (in dbSNP:rs55924090)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042397"
FT   VARIANT         574
FT                   /note="K -> N (in dbSNP:rs56040619)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042398"
FT   VARIANT         720
FT                   /note="T -> S (in a breast infiltrating ductal carcinoma
FT                   sample; somatic mutation; dbSNP:rs1040254222)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042399"
FT   VARIANT         830
FT                   /note="M -> V (in a gastric adenocarcinoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042400"
FT   VARIANT         949
FT                   /note="F -> Y (in dbSNP:rs55681028)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042401"
FT   VARIANT         1033
FT                   /note="A -> G (in dbSNP:rs34530969)"
FT                   /id="VAR_052381"
FT   VARIANT         1046
FT                   /note="G -> D (probable disease-associated variant found in
FT                   a patient with hypomagnesemia and secondary hypocalcemia;
FT                   de novo variant; causes severely reduced Mg(2+) uptake in
FT                   transfected cells)"
FT                   /evidence="ECO:0000269|PubMed:35561741"
FT                   /id="VAR_086707"
FT   VARIANT         1064
FT                   /note="Q -> R (in dbSNP:rs56298128)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042402"
FT   VARIANT         1145
FT                   /note="I -> V (in dbSNP:rs34711809)"
FT                   /id="VAR_052382"
FT   VARIANT         1211
FT                   /note="I -> T (in dbSNP:rs56090496)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042403"
FT   VARIANT         1254
FT                   /note="A -> V (in dbSNP:rs56288221)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042404"
FT   VARIANT         1306
FT                   /note="D -> E (in dbSNP:rs55970334)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042405"
FT   VARIANT         1444
FT                   /note="R -> K (in dbSNP:rs55840070)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042406"
FT   VARIANT         1482
FT                   /note="T -> I (mutant channels are functional but show
FT                   increased susceptibility to inhibition by intracellular
FT                   magnesium concentrations compared to wild-type channels;
FT                   dbSNP:rs8042919)"
FT                   /evidence="ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:16051700, ECO:0000269|PubMed:17344846"
FT                   /id="VAR_019967"
FT   MUTAGEN         1648
FT                   /note="K->R: Loss of kinase activity."
FT                   /evidence="ECO:0000269|PubMed:12887921"
FT   MUTAGEN         1799
FT                   /note="G->D: Loss of kinase activity."
FT                   /evidence="ECO:0000269|PubMed:12887921"
FT   CONFLICT        573..575
FT                   /note="EKM -> KKK (in Ref. 4; BAD18773)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        998
FT                   /note="A -> S (in Ref. 5)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1496
FT                   /note="Missing (in Ref. 3; AAK19738)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1520
FT                   /note="D -> V (in Ref. 3; AAK19738)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   1865 AA;  212697 MW;  BE732674D52D7485 CRC64;
     MSQKSWIEST LTKRECVYII PSSKDPHRCL PGCQICQQLV RCFCGRLVKQ HACFTASLAM
     KYSDVKLGDH FNQAIEEWSV EKHTEQSPTD AYGVINFQGG SHSYRAKYVR LSYDTKPEVI
     LQLLLKEWQM ELPKLVISVH GGMQKFELHP RIKQLLGKGL IKAAVTTGAW ILTGGVNTGV
     AKHVGDALKE HASRSSRKIC TIGIAPWGVI ENRNDLVGRD VVAPYQTLLN PLSKLNVLNN
     LHSHFILVDD GTVGKYGAEV RLRRELEKTI NQQRIHARIG QGVPVVALIF EGGPNVILTV
     LEYLQESPPV PVVVCEGTGR AADLLAYIHK QTEEGGNLPD AAEPDIISTI KKTFNFGQNE
     ALHLFQTLME CMKRKELITV FHIGSDEHQD IDVAILTALL KGTNASAFDQ LILTLAWDRV
     DIAKNHVFVY GQQWLVGSLE QAMLDALVMD RVAFVKLLIE NGVSMHKFLT IPRLEELYNT
     KQGPTNPMLF HLVRDVKQGN LPPGYKITLI DIGLVIEYLM GGTYRCTYTR KRFRLIYNSL
     GGNNRRSGRN TSSSTPQLRK SHESFGNRAD KKEKMRHNHF IKTAQPYRPK IDTVMEEGKK
     KRTKDEIVDI DDPETKRFPY PLNELLIWAC LMKRQVMARF LWQHGEESMA KALVACKIYR
     SMAYEAKQSD LVDDTSEELK QYSNDFGQLA VELLEQSFRQ DETMAMKLLT YELKNWSNST
     CLKLAVSSRL RPFVAHTCTQ MLLSDMWMGR LNMRKNSWYK VILSILVPPA ILLLEYKTKA
     EMSHIPQSQD AHQMTMDDSE NNFQNITEEI PMEVFKEVRI LDSNEGKNEM EIQMKSKKLP
     ITRKFYAFYH APIVKFWFNT LAYLGFLMLY TFVVLVQMEQ LPSVQEWIVI AYIFTYAIEK
     VREIFMSEAG KVNQKIKVWF SDYFNISDTI AIISFFIGFG LRFGAKWNFA NAYDNHVFVA
     GRLIYCLNII FWYVRLLDFL AVNQQAGPYV MMIGKMVANM FYIVVIMALV LLSFGVPRKA
     ILYPHEAPSW TLAKDIVFHP YWMIFGEVYA YEIDVCANDS VIPQICGPGT WLTPFLQAVY
     LFVQYIIMVN LLIAFFNNVY LQVKAISNIV WKYQRYHFIM AYHEKPVLPP PLIILSHIVS
     LFCCICKRRK KDKTSDGPKL FLTEEDQKKL HDFEEQCVEM YFNEKDDKFH SGSEERIRVT
     FERVEQMCIQ IKEVGDRVNY IKRSLQSLDS QIGHLQDLSA LTVDTLKTLT AQKASEASKV
     HNEITRELSI SKHLAQNLID DGPVRPSVWK KHGVVNTLSS SLPQGDLESN NPFHCNILMK
     DDKDPQCNIF GQDLPAVPQR KEFNFPEAGS SSGALFPSAV SPPELRQRLH GVELLKIFNK
     NQKLGSSSTS IPHLSSPPTK FFVSTPSQPS CKSHLETGTK DQETVCSKAT EGDNTEFGAF
     VGHRDSMDLQ RFKETSNKIK ILSNNNTSEN TLKRVSSLAG FTDCHRTSIP VHSKQAEKIS
     RRPSTEDTHE VDSKAALIPD WLQDRPSNRE MPSEEGTLNG LTSPFKPAMD TNYYYSAVER
     NNLMRLSQSI PFTPVPPRGE PVTVYRLEES SPNILNNSMS SWSQLGLCAK IEFLSKEEMG
     GGLRRAVKVQ CTWSEHDILK SGHLYIIKSF LPEVVNTWSS IYKEDTVLHL CLREIQQQRA
     AQKLTFAFNQ MKPKSIPYSP RFLEVFLLYC HSAGQWFAVE ECMTGEFRKY NNNNGDEIIP
     TNTLEEIMLA FSHWTYEYTR GELLVLDLQG VGENLTDPSV IKAEEKRSCD MVFGPANLGE
     DAIKNFRAKH HCNSCCRKLK LPDLKRNDYT PDKIIFPQDE PSDLNLQPGN STKESESTNS
     VRLML
//
